SPARC

Blocking peptide for use with SPARC antibodies (Cat. Nos. X1860P & X1867P).

SPARC is a key factor in cell-matrix interactions and possibly tumour aggressiveness. The SPARC gene, which encodes a multifunctional glycoprotein with roles in tissue development, remodelling and fibrosis. A regulator of cell-extracellular matrix (ECM) interactions, SPARC represents a major factor in the ECM remodelling occurring during tumour invasion. in silico analysis reveals 4 UTR-SNPs located in the 3 -UTR of the SPARC gene, corresponding to 1474 g a, 1551 g c, 1922 t g and 2072 c t changes, which are significantly associated with tumoral state of the tissue. Of all hits, the 2072 SPARC polymorphism had the best association with cancer.SPARC therefore is a gene involved in a number of diseases including rheumatoid arthritis, scleroderma, tumor development and metastasis. SPARC variants have been detected in tumour samples of patients with acute myeloblastic leukemia (AML).

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.

See vial for concentration

Signal Transduction

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Antibody Function Blocking

Unconjugated

Products are stable for one year from purchase when stored properly

Secreted Protein Acidic and Rich in Cysteine, Secreted modular calcium-binding protein 2, SMOC-2, Smooth muscle-associated protein 2, SMAP-2

Q9H3U7